A detailed history of Federated Hermes, Inc. transactions in Allakos Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 9,612 shares of ALLK stock, worth $9,035. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,612
Previous 8,671 10.85%
Holding current value
$9,035
Previous $8,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.54 - $0.92 $508 - $865
941 Added 10.85%
9,612 $6,000
Q2 2024

Aug 08, 2024

SELL
$1.0 - $1.45 $49 - $71
-49 Reduced 0.56%
8,671 $8,000
Q1 2024

May 14, 2024

BUY
$1.02 - $3.23 $8,894 - $28,165
8,720 New
8,720 $10,000
Q1 2023

May 08, 2023

SELL
$4.3 - $8.27 $205,927 - $396,050
-47,890 Reduced 3.04%
1,527,065 $6.8 Million
Q4 2022

Feb 13, 2023

SELL
$5.66 - $8.42 $1.05 Million - $1.57 Million
-186,329 Reduced 10.58%
1,574,955 $13.3 Million
Q3 2022

Nov 14, 2022

SELL
$3.02 - $6.12 $1,760 - $3,567
-583 Reduced 0.03%
1,761,284 $10.8 Million
Q2 2022

Aug 15, 2022

BUY
$2.6 - $6.14 $4.24 Million - $10 Million
1,629,344 Added 1229.48%
1,761,867 $5.52 Million
Q1 2022

May 13, 2022

BUY
$5.08 - $9.81 $673,216 - $1.3 Million
132,523 New
132,523 $755,000
Q3 2021

Nov 15, 2021

SELL
$76.53 - $110.43 $2,602 - $3,754
-34 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$85.37 - $114.1 $518,110 - $692,472
-6,069 Reduced 99.44%
34 $3,000
Q1 2021

May 13, 2021

SELL
$109.73 - $153.66 $1.01 Million - $1.42 Million
-9,210 Reduced 60.14%
6,103 $701,000
Q4 2020

Feb 12, 2021

BUY
$79.58 - $152.45 $1.22 Million - $2.33 Million
15,313 New
15,313 $2.14 Million
Q2 2020

Aug 13, 2020

SELL
$44.04 - $80.69 $2,290 - $4,195
-52 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$44.49 - $93.39 $2,313 - $4,856
52 New
52 $2,000
Q4 2019

Feb 14, 2020

SELL
$66.49 - $137.73 $692,892 - $1.44 Million
-10,421 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$31.0 - $89.73 $323,051 - $935,076
10,421 New
10,421 $819,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $79.6M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.